China Medical GatewayLoading your healthcare gateway…

Lung Cancer in China

Overview

Lung cancer arises in the airways or lung tissue, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. Over the past decade outcomes have been transformed by low-dose CT screening, minimally invasive surgery and targeted and immune therapies matched to each tumor’s biology.

China diagnoses and treats the world’s largest lung cancer population; its national cancer centers offer genomic profiling, robotic resection and domestically developed targeted drugs, several of which reached clinical use years ahead of some international markets.

Symptoms & Signs

Persistent cough, or a change in the character of a long-standing smoker’s cough

Coughing up blood, chest pain and breathlessness

Recurrent pneumonia or bronchitis in the same lung region

Unexplained weight loss, fatigue and loss of appetite

Hoarseness from recurrent laryngeal nerve involvement, or facial swelling from vessel compression

Early-stage tumors often cause no symptoms and are found on low-dose CT screening

Diagnosis

Low-dose CT for screening and pulmonary nodule detection in high-risk individuals

PET-CT for whole-body staging of proven cancers

Bronchoscopy with biopsy, navigational bronchoscopy or CT-guided needle biopsy for tissue

EBUS-TBNA minimally invasive staging of mediastinal lymph nodes

Next-generation sequencing (NGS) profiling EGFR, ALK, ROS1, KRAS and PD-L1 to guide therapy

Molecular liquid biopsy for genotyping and treatment monitoring

Treatment Options

Minimally invasive (VATS or robotic) lobectomy with lymph node dissection for operable early disease

Sublobar (segmentectomy) resection for small screen-detected nodules, preserving lung function

SBRT stereotactic body radiotherapy delivering curative doses for patients unfit for surgery

Targeted therapy (EGFR, ALK, ROS1 inhibitors) for driver-mutation cancers, often as first-line treatment

Immunotherapy (PD-1/PD-L1 inhibitors) alone or with chemotherapy for mutation-negative disease

Multidisciplinary combined-modality care for stage III disease and oligometastatic cases

Advanced Technologies & Novel Drug

da Vinci robotic and single-port VATS lung resection

Navigational and robotic bronchoscopy reaching peripheral nodules for early diagnosis

Next-generation sequencing platforms with rapid turnaround

Domestically developed EGFR inhibitors (e.g. aumolertinib-class) and anti-PD-1 agents approved first in China

Novel antibody-drug conjugates for refractory disease available through major cancer centers

Hospital & Specialist

Return to Home